Shenzhen-based Chinese gene sequencing giant BGI Genomics Co., Ltd is making another try for a listing on the ChiNext board of the Shenzhen Stock Exchange, seeking to raise US$250 million by issuing 40 million new shares, after its previous application was rejected last November.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access Over 11,000 stories and data posts over the past 8 years!
Register Now